SCHEMBL3768944

SCHEMBL3768944

CCOC(=O)c1ccc(N2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.53
POLB P06746 1/20 0.53
TSHR P16473 2/20 0.51
LMNA P02545 3/20 0.49
MAPT P10636 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
GFER P55789 1/20 0.47
HRH3 Q9Y5N1 3/20 0.47
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
ITGB3 P05106 1/20 0.46
ITGA2B P08514 1/20 0.46
ALOX15 P16050 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CALCA P06881 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3776093 0.97 ALDH1A1 (0.50) ALDH1A1POLBTSHRLMNAMAPT
SCHEMBL63892 0.89 ALDH1A1 (0.63) ALDH1A1POLBTSHRMAPTSMN1; SMN2
SCHEMBL3772187 0.88 MAPT (0.48) ALDH1A1POLBTSHRLMNAMAPT
SCHEMBL6135228 0.87 ALDH1A1 (0.67) ALDH1A1POLBTSHRSMN1; SMN2HRH3
SCHEMBL3765368 0.86 ALDH1A1 (0.51) ALDH1A1LMNAMAPTSMN1; SMN2GFER
SCHEMBL3767816 0.86 MEN1 (0.58) ALDH1A1LMNAMAPTSMN1; SMN2GFER
SCHEMBL3775652 0.86 LMNA (0.58) ALDH1A1LMNAMAPTSMN1; SMN2GFER
SCHEMBL6134915 0.85 ALDH1A1 (0.65) ALDH1A1POLBTSHRSMN1; SMN2MEN1
SCHEMBL13006657 0.85 ALDH1A1 (0.58) ALDH1A1LMNAMAPTSMN1; SMN2GFER
SCHEMBL63474 0.84 ALDH1A1 (0.59) ALDH1A1POLBTSHRLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885POLB 4363/4885TSHR 436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.